Economics of diabetes-cost impact of not treating diabetes early and intensively

Clinical Cornerstone

Volumn 6, Issue 2, 2004, Pages 51-58

  Cefalu, William ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; PRAVASTATIN; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DISEASE COURSE; EPIDEMIC; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PREVALENCE; PREVENTIVE MEDICINE; RISK REDUCTION; STROKE; TREATMENT PLANNING; UNITED STATES;

CARDIOVASCULAR DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; RISK FACTORS; UNITED STATES;

EID: 12344326576     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(04)80054-1     Document Type: Article

References (27)

1. DeFronzo R.A. Insulin resistance, hyperinsulinemia, and coronary artery disease: A complex metabolic web J Cardiovasc Pharmacol. 20 Suppl 11 1992 S1-S16
2. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1988 1595-1607
3. Haffner S.M. The insulin resistance syndrome revisited Diabetes Care 19 1996 275-277
4. Liese A.D. Mayer-Davis E.J. Haffner S.M. Development of the multiple metabolic syndrome: An epidemiologic perspective Epidemiol Rev. 20 1998 157-172
5. Isomaa B. Almgren P. Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683-689
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111) JAMA 285 2001 2486-2497
7. Hunter S.J. Garvey W.T. Insulin action and insulin resistance: Diseases involving defects in insulin receptors, signal transduction, and the glucose transport effectorsystem Am J Med. 105 1998 331-345
8. Cefalu W.T. Insulin resistance In: Leahy J. Clark N. Cefalu W.T. eds The Medical Management of Diabetes Mellitus 2000 Marcel Dekker New York, NY 57-75
9. Kahn S.E. The importance of the beta-cell in the pathogenesis of type 2 diabetes Am J Med. 108 Suppl 6A 2000; 2S-8S
10. Buchanan T.A. Pancreatic beta-cell loss and preservation in type 2 diabetes Clin Ther. 25 Suppl B 2003 B32-B46
11. Weyer C. Bogardus C. Mott D.M. Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest. 104 1999 787-794
12. Weyer C. Tataranni P.A. Bogardus C. Pratley R.E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose toler ance during each stage of type 2 diabetes development Diabetes Care 24 2001 89-94
13. McLaughlin T. Allison G. Abbasi F. et al. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals Metabolism 53 2004 495-499
14. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease Curr Med Res Opin. 20 2004 295-304
15. Lakka H.M. Laaksonen D.E. Lakka T.A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709-2716
16. Hu F.B. Stampfer M.J. Haffner S.M. et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care 25 2002 1129-1134
17. Centers for Disease Control and Prevention (CDC) Diabetes prevalence among American Indians and Alaska Natives and the overall population-United States, 1994-12 MMWR Morb Mortal Wkly Rep. 52 2003 702-704
18. Mokdad A.H. Ford E.S. Bowman B.A. et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 JAMA 289 2003 76-79
19. Ford E.S. Giles W.H. Dietz W.H. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey JAMA 287 2002 356-359
20. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation WHO Technical Report Series, 894 2000 World Health Organization Geneva, Switzerland
21. Evans R.M. Barish G.D. Wang Y.U. PPARs and the complex journey to obesity Nat Med. 10 2004 355-361
22. American Diabetes Association Economic costs of diabetes in the US in 2002 Diabetes Care 26 2003 917-932
23. Brandle M. Zhou H. Smith B.R.K. The direct medical cost of type 2 diabetes Diabetes Care 26 2003 2300-2304
24. The Diabetes Prevention Program Research Group Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes Diabetes Care 26 2003 2518-2523
25. The Centers for Disease Control and Prevention Diabetes Cost-Effectiveness Group Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol reduction for type 2 diabetes JAMA 287 2002 2542-2552
26. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854-865
27. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 35) Lancet 352 1998 837-853